Plain-English translation of NCT07675070 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying how well and how safely (Amitzo, NanoAlvand) works in patients with advanced brain tumors. Researchers will follow 100 patients in Iran who receive this medication and carefully track any side effects, especially effects on the liver. The study will help doctors understand whether this particular version of the medication is safe and effective for treating these serious brain cancers.
This medication has been used to treat brain tumors for years, but researchers want to gather detailed safety information about this specific formulation. By carefully monitoring patients and documenting their experiences, doctors can better understand how well the treatment works and what side effects patients might experience.
You likely qualify if…
You likely don't qualify if…
You would receive the medication during the first 5 days of each 28-day treatment cycle. You would attend 6 study visits plus a final follow-up visit, where your doctor will check on your health and watch for any side effects. Throughout the study, your doctor will fill out detailed records about how you're responding to the medication and any changes in your condition.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Iran
Enrollment target
~100 participants
Started
March 2026
Primary completion
September 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nassim Anjidani, PharmD
Iran University of Medical Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.